Boston Therapeutics, Inc.
BTHE · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -1,434.8% |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -25,110.7% |
| Other Income/Exp. Net | -$2 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -32,663.7% |
| EPS | -2.7 | -0.004 | -0.02 | -0.003 |
| % Growth | -69,130.8% | 80.8% | -534.4% | – |
| EPS Diluted | -2.7 | -0.004 | -0.02 | -0.003 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$3 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -19,104% |